Kedrion and Kamada partner up for anti-COVID-19 IgG product
![](/46/pdcnewsitem/10/99/13/HLN00CPO-immunoglobulins%20fighting%20coronavirus.jpg)
Human plasma-derived product will be developed and manufactured utilizing Kamada’s proprietary IgG platform technology
Kamada and Kedrion Biopharma have agreed a global collaboration for the development, manufacturing and distribution of a human plasma-derived Anti-SARs-COV-2 (COVID-19) polyclonal immunoglobulin (IgG) product as a potential treatment for coronavirus patients, the plasma-focused biopharma firms said on Wednesday.
The IgG product will be developed and manufactured using Kamada’s proprietary IgG platform technology.
Under the terms of the agreement, Kamada will be responsible for product development, manufacturing, clinical development, with Kedrion’s support, and regulatory submissions.
Kedrion will provide plasma, collected at its KEDPLASMA centres, from donors who have recovered from the virus. Upon regulatory approval, it will be responsible for commercialization in the US, Europe, Australia, and South Korea.
Kamada will distribute the treatment in all territories outside of those Kedrion is responsible for and marketing rights for the product in China will be shared by both firms.
The collaboration will initially focus on providing the treatment to patients in Italy, Israel and the US through various clinical programmes, while expanding development and commercialization efforts to additional markets, the firms said.
“In light of the current global coronavirus outbreak, Kedrion and Kamada have quickly focused their efforts on developing and manufacturing a potentially safe and effective treatment,” said Paolo Marcucci, chief executive officer of Kedrion. “Based on our collective expertise in plasma-derived protein therapeutics, we believe Kedrion and Kamada are uniquely positioned to develop, manufacture and supply, in a relatively short period of time, an Anti-SARs-COV-2 IgG treatment.”
Kamada’s Chief Executive Officer, Amir London, said his company intends to begin clinical manufacturing shortly.
“I am confident that the collaboration with Kedrion, a global leader in plasma collection and plasma-derived therapeutics, will allow us to speed up the development of the product and strengthen our international reach,” he added.
The partners have an existing strategic supply and distribution agreement for KEDRAB, a plasma-derived FDA-approved human rabies immune globulin that was launched in the US in April 2018.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance